The share of Canadian patents transferred to foreign buyers climbed from 18% to 45% between 1998 and 2017. For investors, the IP retention metric is a leading indicator of long-term value creation.
The systematic transfer of Canadian intellectual property to foreign entities has reached a tipping point. Between 1998 and 2017, the share of Canadian patents transferred to foreign buyers climbed from 18% to 45%, according to research cited by Adam Froman, founder and CEO of Delvinia. That shift is not a statistical curiosity. It is a direct drain on the valuation of Canadian technology companies and a signal that founders are treating IP as a cost to be offloaded rather than the primary engine of enterprise value.
Froman, who built and sold two data and research-platform businesses without taking a dollar of venture capital, argues that IP is the financing instrument most Canadian founders are leaving on the table. His experience at AskingCanadians and Methodify provides a concrete template for how IP-first thinking changes the capital structure, the growth trajectory, and the exit multiple.
The headline number is stark. The near-tripling of patent outflows over two decades means Canadian innovation is being monetized elsewhere. Founders are selling their IP to foreign buyers rather than using it to scale domestically. The reason is not a lack of talent or ambition. It is a fundamental misunderstanding of what IP is for.
The 45% figure captures a structural failure. When a founder sells a patent portfolio early, they are trading the engine for gas money. The IP is what enables global scale. Selling it early locks in a fraction of the value that could have been compounded through retained ownership and further development.
Most founders see IP as a legal artifact, something you hand to a lawyer after you have built something worth protecting. Froman's thesis is that this sequence is backwards. IP is a financing instrument, a growth lever, and the primary determinant of what a company is worth at exit. When IP is treated as an afterthought, the company is already priced for a subscale outcome.
Delvinia's experience demonstrates the mechanism. When the company was developing AskingCanadians, an online research community, and later Methodify, an automated research platform, it embedded IP thinking into the DNA of the business from the start.
Key insight: Every dollar invested in proprietary technology and data capability was recoverable–up to 75 cents on the dollar–through government programs, including SR&ED tax credits and National Research Council of Canada Industrial Research Assistance Program (IRAP) grants.
The Scientific Research and Experimental Development (SR&ED) tax credit and IRAP grants created a self-reinforcing cycle. Each dollar spent on proprietary technology returned up to 75 cents in recoverable credits and grants. That recovery funded the next round of research and development, which deepened the IP moat. The deeper the IP, the higher the valuation. The IP was not incidental to the financing model; it was the financing model.
Delvinia eventually sold both companies without ever taking a dollar of venture capital. The founders owned what they built and sold on their terms. The IP-first approach replaced dilution with government-backed recovery, turning R&D into a capital-efficient growth engine. For founders watching their equity shrink with each funding round, the Delvinia path is a practical alternative.
Many Canadian founders believe they face a binary choice: sell the IP to a foreign buyer or attempt to scale globally with limited resources. Froman calls this a false choice. The IP is what enables the global scale. Selling it early is trading the engine for gas money.
When a founder sells a patent portfolio to a U.S. or European acquirer, they capture a one-time gain. The acquirer then uses that IP to build a product, capture market share, and generate recurring revenue streams that the Canadian company could have owned. The difference in enterprise value between a one-time IP sale and a retained-IP global scale-up is often an order of magnitude.
A company with $20 million in recurring revenue built on proprietary technology is not a credit risk. It is a national asset. The current financing ecosystem, however, does not treat it that way. Canadian banks struggle to assess the value of knowledge-based businesses, leaving founders with fewer options to borrow against their IP. That forces premature exits.
IP is the primary determinant of exit value. When Delvinia went to market, the proprietary technology and data capability were the assets that commanded the premium. The buyers were not acquiring a services business; they were acquiring a defensible platform with embedded IP.
Froman's exit terms were shaped by the IP depth. Because the company had not diluted its equity through venture rounds, the founders retained control of the negotiation. The IP moat gave them pricing power. The result was a sale on their terms, not a fire sale driven by a cash runway.
For every Canadian founder who sells IP early, the long-term cost is the forgone enterprise value of a scaled, IP-rich company. The 45% patent transfer rate suggests that cost is being paid repeatedly across the ecosystem. The capital that leaves the country with each IP sale is capital that could have funded the next generation of Canadian technology leaders.
Froman outlines three specific policy shifts that would change the incentive structure for founders and keep more IP at home.
Companies that apply for SR&ED credits or IRAP grants should be required to demonstrate an IP strategy, not just an R&D activity. The current system funds activity without requiring a plan for retention. Making IP integration a condition of access would force founders to think about ownership from day one.
A company with $20 million in recurring revenue built on proprietary technology should be treated as a creditworthy asset, not a risk. The Business Development Bank of Canada (BDC) should lead on developing IP-based lending frameworks that the chartered banks can follow. IP-backed loans would give founders an alternative to selling equity or selling the IP itself.
The loan guarantee program for technology scale-ups should be explicitly tied to IP retention. Capital that keeps a Canadian company Canadian and growing domestically should be the easiest capital to access, not the hardest. This would directly counter the incentive to sell IP to foreign buyers.
For traders and investors tracking Canadian technology names, the IP retention metric is a leading indicator of long-term value creation. Companies that treat IP as a financing lever and a moat tend to command higher multiples and resist premature acquisition. The pattern is similar to the one discussed in The Stethoscope Took Decades. Markets Miss the Same Pattern.: the market often undervalues structural advantages until they become impossible to ignore.
Practical rule: A founder who treats IP as a cost center is already pricing the company for a subscale exit. A founder who treats IP as a financing engine is building a company that can scale on its own terms.
The 45% patent transfer rate is a market signal that Canadian IP is being mispriced. The companies that will define Canada's next economic chapter are being built right now. Whether Canada keeps them depends on whether founders treat IP as the growth engine it is, and whether the government builds the conditions that make keeping it here the rational choice. For investors, the watchlist question is simple: which Canadian tech companies are building IP moats, and which are quietly selling them?
Drafted by the AlphaScala research model and grounded in primary market data – live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.